
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant is expected to have a positive outlook due to the growth in R&D expenses for the development of IMVT-1402, which has shown promising results in reducing levels of pathogenic IgG antibodies in autoimmune diseases. The decline in G&A expenses also indicates efficient cost management. With a strong cash position of $994.5M, Immunovant is well-positioned to continue their operations and support the potential launch of IMVT-1402 in GD, further solidifying its future growth potential.
Bears say
Immunovant is facing significant competition and potential risk of clinical failure as Janssen's trial with a similar drug failed to show added efficacy. Despite a differentiated trial design and patient population, the potential for significant sales in the Difficult-to-Treat RA market may not be fully reflected in the stock's current valuation. Additionally, the company's financials may be impacted by the overenrollment in their Phase 2b study, and the potential for a low placebo rate may obscure the true efficacy of the drug.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares